Last reviewed · How we verify
infusion of NMDA antagonist
infusion of NMDA antagonist is a Small molecule drug developed by New York State Psychiatric Institute. It is currently in Phase 1 development. Also known as: NMDA antagonist.
At a glance
| Generic name | infusion of NMDA antagonist |
|---|---|
| Also known as | NMDA antagonist |
| Sponsor | New York State Psychiatric Institute |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Feeling abnormal
- Dizziness
- Disturbance in attention
- Visual impairment
- Hypoaesthesia
- Dissociation
- Speech disorder
- Sedation
- Fatigue
- Auditory disorder
- Dry mouth
- Confusional state
Key clinical trials
- Management of Pain in Lumbar Arthrodesis (PHASE4)
- Neurobiology of Suicide (PHASE2)
- Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial (PHASE3)
- Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder (PHASE1)
- First-In-Human (FIH), Single Ascending Dose (SAD) Study and Multiple Ascending Dose (MAD) Study of SP-101 Injection (PHASE1)
- Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine (EARLY_PHASE1)
- Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU (PHASE3)
- : Vascular Function in Health and Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- infusion of NMDA antagonist CI brief — competitive landscape report
- infusion of NMDA antagonist updates RSS · CI watch RSS
- New York State Psychiatric Institute portfolio CI
Frequently asked questions about infusion of NMDA antagonist
What is infusion of NMDA antagonist?
infusion of NMDA antagonist is a Small molecule drug developed by New York State Psychiatric Institute.
Who makes infusion of NMDA antagonist?
infusion of NMDA antagonist is developed by New York State Psychiatric Institute (see full New York State Psychiatric Institute pipeline at /company/new-york-state-psychiatric-institute).
Is infusion of NMDA antagonist also known as anything else?
infusion of NMDA antagonist is also known as NMDA antagonist.
What development phase is infusion of NMDA antagonist in?
infusion of NMDA antagonist is in Phase 1.
What are the side effects of infusion of NMDA antagonist?
Common side effects of infusion of NMDA antagonist include Feeling abnormal, Dizziness, Disturbance in attention, Visual impairment, Hypoaesthesia, Dissociation.
Related
- Manufacturer: New York State Psychiatric Institute — full pipeline
- Also known as: NMDA antagonist
- Compare: infusion of NMDA antagonist vs similar drugs
- Pricing: infusion of NMDA antagonist cost, discount & access